U.S. markets open in 4 hours 29 minutes

Avidity Biosciences, Inc. (RNA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
28.15-0.74 (-2.56%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close28.89
Open29.03
Bid0.00 x 900
Ask0.00 x 900
Day's Range26.85 - 29.16
52 Week Range23.06 - 37.46
Volume241,018
Avg. Volume213,018
Market Cap1.056B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est43.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Avidity Biosciences to Present at Several Upcoming Virtual Scientific Meetings
    PR Newswire

    Avidity Biosciences to Present at Several Upcoming Virtual Scientific Meetings

    Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will present at several upcoming virtual scientific meetings.

  • Avidity Biosciences (NASDAQ:RNA) Is In A Good Position To Deliver On Growth Plans
    Simply Wall St.

    Avidity Biosciences (NASDAQ:RNA) Is In A Good Position To Deliver On Growth Plans

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

  • Avidity Biosciences Enters into Collaboration to Study the Natural History of Myotonic Dystrophy Type 1
    PR Newswire

    Avidity Biosciences Enters into Collaboration to Study the Natural History of Myotonic Dystrophy Type 1

    Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced it entered into a collaboration supporting END-DM1, a natural history study to advance the understanding of disease progression in patients with myotonic dystrophy type 1 (DM1). END-DM1 (Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1) is a non-interventional study designed and run by the Myotonic Dystrophy Clinical Research Network (DMCRN), a network of medical centers that aims to support future clinical trials of potential therapies for DM1 through the generation of evidence around endpoint measures and testing methods.